Biogen (BIIB) FY2025 10-K Annual Report
Biogen (BIIB) 10-K annual report for fiscal year 2025, filed with SEC EDGAR on Feb 6, 2026. This page provides AI-powered analysis including business overview, management discussion & analysis (MD&A), risk factors, and key financial data such as revenue, net income, gross margin, operating margin, and return on equity (ROE) extracted from XBRL.
Biogen FY2025 10-K Analysis
Business Overview
- • Core business model: Global biopharmaceutical company developing and commercializing therapies primarily for neurology, specialized immunology, and rare diseases
- • New or emphasized segment: Expanded collaboration with Genentech on multiple anti-CD20 therapies including recently approved GAZYVA for lupus nephritis in Oct 2025
- • Strategic shift: Increased focus on biosimilars portfolio commercialization, including BENEPALI, IMRALDI, and FLIXABI as key growth drivers
- • Quantitative highlight: Acquired in-process research and development expense surged to $471.8M in 2025 from $61.5M in 2024, signaling aggressive pipeline investment
- • Noteworthy fact: Completed agreement to acquire Reata Pharmaceuticals (2023 filing) reflected in continued integration and intangible assets balancing $9.18B as of Dec 2025
Management Discussion & Analysis
- • No specific revenue or YoY change figures disclosed in provided text
- • No profitability or margin figures mentioned
- • No segment performance data provided
- • Capital investments include new biologics manufacturing facility in Solothurn, Switzerland; expansion supports LEQEMBI and TYSABRI production
- • Future growth dependent on new product development, regulatory approvals, patent protection, and external business opportunities
Risk Factors
- • Regulatory risk: IRA Medicare Part D redesign caused $90 million 2025 revenue loss, impacting SKYCLARYS and MS portfolio with future pricing enforcement uncertainty
- • Geopolitical risk: Russia-Ukraine conflict may disrupt supply; revenues from Russia, Ukraine, Middle East each <2.0% of total revenue in 2023-2025
- • Supply chain risk: TECFIDERA, VUMERITY, LEQEMBI raw materials and components partly sourced outside U.S., with tariffs and supplier substitution risks
- • Competitive risk: TECFIDERA patent revoked by European Patent Office Nov 2025; multiple generic entrants causing significant revenue erosion
- • Financial risk: $1.75 billion 2025 Senior Notes issuance with proceeds used to redeem $4.050% notes; $4.2 billion cash and equivalents end 2025
Biogen FY2025 Key Financial MetricsXBRL
Revenue
$9.9B
▲ +2.2% YoY
Net Income
$1.3B
▼ -20.8% YoY
Net Margin
13.1%
▼ -380bp YoY
ROE
7.1%
▼ -268bp YoY
Total Assets
$29.4B
▲ +5.0% YoY
EPS (Diluted)
$8.79
▼ -21.4% YoY
Operating Cash Flow
$2.2B
▼ -23.3% YoY
Source: XBRL data from Biogen FY2025 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on Biogen
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.